Skip to main content

Nektar Therapeutics (NKTR) is expected to report a quarterly loss of 69 cents a share on sales of $27.7 million after the market closes on Wednesday, based on a FactSet survey of 11 analysts.

In the same period a year ago, the company posted a loss of 60 cents a share on sales of $38 million.

The stock has fallen 19.4% since the company last reported earnings on Feb. 28.

Scroll to Continue

TheStreet Recommends

Quarterly estimates have fallen less than 1 cent a share in the past month.

Nektar Therapeutics is currently trading at a price-to-forward-earnings ratio of -11.7 based on the 12-month estimates of 12 analysts surveyed by FactSet.

Jim Cramer and the Action Alerts Plus team are watching the pharmaceuticals sector. To find out what stocks they like in the industry click here now to get more from Action Alerts PLUS.

Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you. Learn how to create tax-efficient income, avoid top mistakes, reduce risk and more. With our courses, you will have the tools and knowledge needed to achieve your financial goals. Learn more about TheStreet Courses on investing and personal finance here